Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

CytomX Therapeutics, Inc. CTMX

Healthcare  —  Biotechnology
2.70 (0.05) (1.82%) as of 25 Sep
Market cap
$599.2M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

CytomX Therapeutics, Inc. (CTMX) Business Profile

Updated before January 2025

Company Overview

CytomX Therapeutics, Inc. (NASDAQ: CTMX) is a clinical-stage biopharmaceutical company dedicated to revolutionizing the field of oncology through the development of innovative therapies. Founded in 2008 and headquartered in South San Francisco, California, CytomX leverages its proprietary Probody® therapeutic platform to create targeted cancer treatments that minimize off-target effects and improve patient outcomes. The company was co-founded by Patrick Baeuerle, a pioneer in the field of immuno-oncology, and has since grown under the leadership of its CEO, Sean McCarthy, Ph.D., who has been instrumental in steering the company’s strategic direction. CytomX’s leadership team comprises seasoned professionals with extensive experience in biotechnology, drug development, and oncology research.

Core Business Segments

CytomX Therapeutics operates primarily in the field of oncology, focusing on the development of Probody® therapeutics. These are antibody-based drugs designed to remain inactive until they reach the tumor microenvironment, thereby reducing systemic toxicity and enhancing efficacy. The company’s core business segments include:

1. Probody® Therapeutics

  • CX-2029: A Probody® drug conjugate targeting CD71, a protein highly expressed in cancer cells. CX-2029 is currently in clinical trials for various solid tumors.
  • CX-904: A T-cell-engaging bispecific antibody targeting EGFR and CD3, designed to activate T-cells specifically within the tumor microenvironment.

2. Partnerships and Collaborations

CytomX has established strategic partnerships with leading pharmaceutical companies, including AbbVie, Amgen, and Bristol Myers Squibb. These collaborations focus on co-developing and commercializing Probody® therapeutics for a range of cancer indications.

3. Research and Development (R&D)

The company invests heavily in R&D to expand its Probody® platform and explore new therapeutic targets. CytomX’s robust pipeline includes multiple preclinical and clinical-stage candidates aimed at addressing unmet medical needs in oncology.

Business Model

CytomX Therapeutics operates on a hybrid business model that combines proprietary drug development with strategic partnerships. The company generates revenue through:

  • Milestone Payments: CytomX receives payments from its partners upon achieving specific developmental, regulatory, and commercial milestones.
  • Royalties: The company earns royalties on net sales of partnered products.
  • Licensing Agreements: CytomX licenses its Probody® platform to partners, enabling them to develop their own therapeutic candidates.

This diversified revenue stream allows CytomX to fund its internal R&D efforts while mitigating financial risks associated with drug development.

Strategic Direction

CytomX is committed to advancing its Probody® platform and expanding its pipeline of innovative cancer therapies. Key strategic priorities include:

  • Pipeline Expansion: The company aims to develop new Probody® therapeutics targeting a broader range of cancers and immune pathways.
  • Global Partnerships: CytomX seeks to strengthen its existing collaborations and establish new partnerships to accelerate the development and commercialization of its therapies.
  • Sustainability Goals: The company is exploring ways to minimize its environmental footprint by adopting sustainable practices in its research and manufacturing processes.
  • Patient-Centric Approach: CytomX is dedicated to improving patient outcomes by developing safer and more effective cancer treatments.

Competitive Landscape

CytomX operates in a highly competitive biopharmaceutical market, facing competition from both established players and emerging startups. Key competitors include:

  • Genentech (a member of the Roche Group): Known for its pioneering work in antibody-based cancer therapies.
  • Amgen: A leader in oncology with a strong portfolio of biologics and small-molecule drugs.
  • MacroGenics: Specializes in bispecific antibodies for cancer treatment.
  • Zymeworks: Focuses on developing multifunctional therapeutics for oncology and other diseases.

Despite the competition, CytomX differentiates itself through its proprietary Probody® platform, which offers a unique approach to targeted cancer therapy.

Risk Factors

Like any biopharmaceutical company, CytomX faces several risks, including:

  • Clinical and Regulatory Risks: The success of CytomX’s pipeline depends on the outcomes of clinical trials and regulatory approvals, which are inherently uncertain.
  • Market Dependence: The company’s revenue is heavily reliant on milestone payments and royalties from its partners.
  • Supply Chain Disruptions: Any disruptions in the supply chain could delay the development and commercialization of CytomX’s therapies.
  • Competition: The biopharmaceutical industry is highly competitive, and the emergence of new technologies could impact CytomX’s market position.

Recent Developments

CytomX has made significant progress in advancing its pipeline and strengthening its partnerships. Recent highlights include:

  • Clinical Trial Updates: Positive interim results from the Phase 2 clinical trial of CX-2029, demonstrating promising efficacy and safety profiles.
  • New Collaborations: Expansion of its partnership with Bristol Myers Squibb to include additional Probody® therapeutic candidates.
  • Corporate Strategy: Implementation of cost-saving measures to optimize operational efficiency and extend the company’s cash runway.

Global developments, such as the COVID-19 pandemic, have posed challenges to clinical trial timelines and supply chain operations. However, CytomX has demonstrated resilience by adapting to these challenges and maintaining progress in its R&D efforts.

Investment Considerations

Strengths

  • Innovative Platform: CytomX’s Probody® technology offers a novel approach to targeted cancer therapy, providing a competitive edge.
  • Strong Partnerships: Collaborations with industry leaders enhance the company’s credibility and financial stability.
  • Robust Pipeline: A diverse pipeline of clinical and preclinical candidates positions CytomX for long-term growth.

Risks

  • Financial Dependence: The company relies heavily on external funding and milestone payments, which may fluctuate.
  • Regulatory Uncertainty: Delays or failures in clinical trials could impact CytomX’s ability to bring products to market.
  • Market Competition: Intense competition in the oncology space poses a constant challenge.

Conclusion

CytomX Therapeutics, Inc. is at the forefront of innovation in oncology, leveraging its proprietary Probody® platform to develop safer and more effective cancer therapies. With a robust pipeline, strong partnerships, and a commitment to patient-centric innovation, CytomX is well-positioned for future growth. However, investors should carefully consider the inherent risks associated with clinical-stage biopharmaceutical companies. Overall, CytomX represents a compelling opportunity for those seeking exposure to the cutting edge of cancer treatment innovation.